- Home
- ANTX vs INKT Comparison
ANTX vs INKT Comparison
Compare ANTX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- INKT
- Stock Information
- Founded
- ANTX 2017
- INKT 2017
- Country
- ANTX United States
- INKT United States
- Employees
- ANTX N/A
- INKT N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- ANTX Health Care
- INKT Health Care
- Exchange
- ANTX Nasdaq
- INKT Nasdaq
- Market Cap
- ANTX 33.2M
- INKT 28.8M
- IPO Year
- ANTX 2022
- INKT 2021
- Fundamental
- Price
- ANTX $1.10
- INKT $25.38
- Analyst Decision
- ANTX Buy
- INKT Hold
- Analyst Count
- ANTX 2
- INKT 3
- Target Price
- ANTX $2.00
- INKT $37.50
- AVG Volume (30 Days)
- ANTX 258.4K
- INKT 2.7M
- Earning Date
- ANTX 08-12-2025
- INKT 08-12-2025
- Dividend Yield
- ANTX N/A
- INKT N/A
- EPS Growth
- ANTX N/A
- INKT N/A
- EPS
- ANTX N/A
- INKT N/A
- Revenue
- ANTX N/A
- INKT N/A
- Revenue This Year
- ANTX N/A
- INKT N/A
- Revenue Next Year
- ANTX N/A
- INKT N/A
- P/E Ratio
- ANTX N/A
- INKT N/A
- Revenue Growth
- ANTX N/A
- INKT N/A
- 52 Week Low
- ANTX $0.87
- INKT $4.56
- 52 Week High
- ANTX $3.07
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- ANTX 48.42
- INKT 58.01
- Support Level
- ANTX $1.05
- INKT $6.80
- Resistance Level
- ANTX $1.10
- INKT $76.00
- Average True Range (ATR)
- ANTX 0.04
- INKT 6.24
- MACD
- ANTX 0.00
- INKT 2.84
- Stochastic Oscillator
- ANTX 50.00
- INKT 29.68
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.